Catalent (CTLT) to Release Quarterly Earnings on Tuesday

Posted by Defense World Staff on Aug 27th, 2023

Catalent (NYSE:CTLT – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, August 29th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Catalent (NYSE:CTLT – Get Free Report) last posted its earnings results on Monday, June 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.08. Catalent had a net margin of 0.93% and a return on equity of 7.13%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $930.44 million. On average, analysts expect Catalent to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Catalent Stock Up 0.7 %

NYSE:CTLT opened at $44.89 on Friday. The firm’s 50 day simple moving average is $45.44 and its 200 day simple moving average is $51.16. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.84 and a quick ratio of 1.34. Catalent has a one year low of $31.45 and a one year high of $104.62. The company has a market cap of $8.09 billion, a PE ratio of 204.05, a P/E/G ratio of 5.83 and a beta of 1.23.

Analyst Ratings Changes

Several equities research analysts recently commented on CTLT shares. JPMorgan Chase & Co. downgraded shares of Catalent from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $90.00 to $45.00 in a research report on Sunday, May 21st. Barclays lifted their target price on shares of Catalent from $35.00 to $42.00 in a research report on Monday, June 12th. Wells Fargo & Company initiated coverage on shares of Catalent in a research report on Thursday, July 20th. They issued an “equal weight” rating and a $43.00 price target on the stock. Morgan Stanley dropped their price target on shares of Catalent from $85.00 to $50.00 in a research report on Monday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Catalent from $37.00 to $45.00 and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Catalent currently has an average rating of “Hold” and a consensus target price of $56.92.

Read Our Latest Research Report on Catalent

Insider Buying and Selling at Catalent

In other Catalent news, CEO Alessandro Maselli sold 2,071 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $44.54, for a total transaction of $92,242.34. Following the completion of the sale, the chief executive officer now owns 88,004 shares in the company, valued at approximately $3,919,698.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 2,071 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $44.54, for a total transaction of $92,242.34. Following the completion of the sale, the chief executive officer now owns 88,004 shares in the company, valued at approximately $3,919,698.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Steven L. Fasman sold 817 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $44.65, for a total transaction of $36,479.05. Following the sale, the executive vice president now owns 73,789 shares of the company’s stock, valued at approximately $3,294,678.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,442 shares of company stock worth $247,577. 0.58% of the stock is owned by corporate insiders.

Institutional Trading of Catalent

Institutional investors have recently made changes to their positions in the company. KB Financial Partners LLC bought a new stake in shares of Catalent in the 1st quarter worth $30,000. Jefferies Financial Group Inc. bought a new stake in shares of Catalent in the 4th quarter worth $61,000. Covestor Ltd grew its stake in shares of Catalent by 84.9% in the 1st quarter. Covestor Ltd now owns 562 shares of the company’s stock worth $62,000 after acquiring an additional 258 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Catalent by 112.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $189,000 after acquiring an additional 2,313 shares in the last quarter. Finally, Veritable L.P. bought a new stake in shares of Catalent in the 1st quarter worth $204,000.

About Catalent

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.